Laekna, Inc.

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:39 28/05/2024 BST			5-day change	1st Jan Change
7.04 ^HKD	+0.14%		-9.16%	-64.62%

05-23	US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%	MT
05-23	Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer	CI

Laekna, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023

August 24, 2023 at 10:17 am

Laekna, Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was CNY 216.99 million compared to CNY 301.93 million a year ago. Basic loss per share from continuing operations was CNY 2.63 compared to CNY 4.08 a year ago.

Latest news about Laekna, Inc.

US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%	05-23	MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer	05-23	CI
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug	05-10	MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102	05-10	CI
Laekna Scores FDA Nod for Obesity Drug LAE102	04-15	MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102	04-15	CI
Laekna Shrinks Loss in Fiscal 2023	03-27	MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug	03-11	MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration	03-11	CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities	03-01	MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102	02-29	CI
Laekna, Inc. Announces Management Changes	02-02	CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%	01-29	MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China	01-28	CI
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer	01-15	CI
Laekna, Inc. Announces Executive Changes	01-15	CI
326,372,350 Shares of Laekna, Inc. are subject to a Lock-Up Agreement Ending on 29-DEC-2023.	12-28	CI
Laekna, Inc.(SEHK:2105) added to S&P Global BMI Index	12-18	CI
Laekna Presents Data from Phase 1B Trial for Cancer Treatment	12-11	MT
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS	12-10	CI
Laekna, Inc. Announces Resignation of Ji Dongmei as Non-Executive Director	29/09/23	CI
Laekna Shrinks Loss in H1	25/08/23	MT
Laekna, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Hong Kong Stocks Drop Over Weak China Data Bets; Laekna Closes 20% Higher at Debut	29/06/23	MT

Chart Laekna, Inc.

Duration

Period

More charts

Company Profile

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LAEKNA, INC.	-64.62%	351M
VERTEX PHARMACEUTICALS INCORPORATED	+9.86%	118B
REGENERON PHARMACEUTICALS, INC.	+10.40%	106B
BIONTECH SE	-11.12%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.52%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.93%	14.03B
SAREPTA THERAPEUTICS, INC.	+18.07%	11.67B

Bio Therapeutic Drugs